Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis: A prospective randomized controlled study

Nephron - Clinical Practice

Volumn 99, Issue 4, 2005, Pages

  Sheashaa, Hussein ^a   Abdel Razek, Waleed ^a   El Husseini, Amr ^a   Selim, Amal ^b   Hassan, Nabil ^a   Abbas, Tarek ^a   El Askalani, Hassan ^b   Sobh, Mohamed ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Anemia; Erythropoietin; Hemodialysis; Nandrolone decanoate

Indexed keywords

ANDROGEN; ERYTHROPOIETIN; HEMOGLOBIN; NANDROLONE DECANOATE; SOMATOMEDIN C;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GYNECOMASTIA; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HIRSUTISM; HUMAN; IRON STORAGE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; MENSTRUAL IRREGULARITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; ANABOLIC AGENTS; ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; NANDROLONE; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 17144374057     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083891     Document Type: Article

References (14)

1. Besarab A, Reyes CM, Hornberger J: Meta-analysis of subcutaneous versus intravenous EPO in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40:439-446.
2. Horl WH: Is there a role for adjuvant therapy in patients being treated with EPO. Nephrol Dial Transplant 1999;14:50-60.
3. Navarro JF, Mora C, Macia M, Garcia J: Randomized prospective comparison between EPO and androgens in CAPD patients. Kidney Int 2002;61:1537-1544.
4. Daugirdas JT, Depner TA: A nomogram approach to hemodialysis urea modeling. Am J Kidney Dis 1994;23:33-40.
5. Daughaday WH, Rotwein P: Insulin-like growth factor-I and -II. Peptides, messenger ribonucleic acid and gene structure, serum and tissue concentrations. Endocr Rev 1989;10: 68-91.
6. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ: Androgens potentiate the effects of EPO in the treatment of anemia of ESRD. Am J Kidney Dis 1991;17:29-33.
7. Berns JS, Rudnick MR, Cohen RM: A controlled trial of recombinant human EPO and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992;37:264-267.
8. Teruel JL, Aguilera A, Marcen R, Navarro-Antolin J, Garcia-Otero G, Ortuno J: Androgen therapy for anemia of chronic renal failure. Indications in EPO era. Scand J Urol Nephrol 1996;30:403-408.
9. Gaughan WJ, Liss KA, Dunn SR, et al: A 6-month study of low-dose recombinant human EPO alone and in combination with androgens for the treatment of anemia in patients on chronic hemodialysis. Am J Kidney Dis 1997; 30:495-500.
10. Lee MS, Ahn SH, Song JH: Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human EPO. Korean J Intern Med 2002;17:167-173.
11. EBPG: European Best Practice Guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2000;15(suppl 4):57-63.
12. Macdougall IC: Poor response to EPO: Practical guidelines on investigation and management. Nephrol Dial Transplant 1995;10:607-614.
13. Vlahakos DV, Balodimos C, Papachristopulous V, Vassilakos P, Hinari E, Vlachojannis JG: Renin-angiotensin system stimulates EPO secretion in chronic hemodialysis patients. Clin Nephrol 1995;43:53-59.
14. Morrone LF, Di Paolo S, Logoluso F, Schena A, Stallone G, Giorgino F, Schena FP: Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines. Transplantation 1997;64:913-918.